{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:12:11Z","timestamp":1778825531776,"version":"3.51.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study evaluates the effectiveness of tracking D-dimer levels and the CRP\/ALB ratio for objective quantification of therapeutic response and complication risk in children with infectious mononucleosis (IM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study involved 171 hospitalized children diagnosed with IM, comprising 116 patients without complications and 55 with complications. Measurements of D-dimer, CRP, albumin, and atypical lymphocytes percentage (ALC) were taken within 24 h of admission and again on the fifth day of treatment to calculate the rate of change. Independent predictors were identified through logistic regression analysis, and the model's performance was validated using receiver operating characteristic (ROC) curves in both training and validation cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Although baseline markers were comparable between groups, post-treatment analysis revealed that the complications group exhibited persistent hypercoagulability and inflammation, as evidenced by elevated levels of D-dimer and CRP\/ALB, along with a slower decline in atypical lymphocytes percentage (ALC) (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). In contrast, the no-complication group demonstrated significantly greater reductions in \u0394D-dimer, \u0394CRP, \u0394ALC, and \u0394CRP\/ALB compared to the complication group. Multivariable analysis identified fever duration, \u0394ALC, \u0394D-dimer and \u0394CRP\/ALB as independent predictors of complications. The composite model achieved an area under the curve (AUC) of 0.91 (95% CI 0.86\u20130.96), with a sensitivity of 0.85 and a specificity of 0.86. The model demonstrated strong performance in the validation cohort, achieving an AUC of 0.93, along with good calibration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short-term changes of routine markers, particularly D-dimer and CRP\/ALB, in conjunction with fever duration, may facilitate the objective evaluation of therapeutic efficacy and assist in risk stratification for complications in pediatric IM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1830883","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:43:55Z","timestamp":1778823835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical utility of combining D-dimer with the C-reactive protein\/albumin ratio for assessing treatment response in pediatric infectious mononucleosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Long Ying","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, First People's Hospital of Linping District","place":["Hangzhou, Zhejiang Province, China"]},{"name":"School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, First People's Hospital of Linping District","place":["Hangzhou, Zhejiang Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shui","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, First People's Hospital of Linping District","place":["Hangzhou, Zhejiang Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuo Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The People's Hospital of Cangnan Zhejiang","place":["Wenzhou, Zhejiang Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0024923","DOI":"10.1128\/aac.00249-23","article-title":"Association between antibiotic exposure and the risk of rash in children with infectious mononucleosis: a multicenter, retrospective cohort study","volume":"67","author":"Zhang","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12889-020-09049-x","article-title":"Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom","volume":"20","author":"Kuri","year":"2020","journal-title":"BMC Public Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/jgid.jgid_38_22","article-title":"Infectious mononucleosis presenting as near-fatal tracheal obstruction","volume":"15","author":"Kumar","year":"2022","journal-title":"J Glob Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"114695","DOI":"10.1016\/j.intimp.2025.114695","article-title":"Long-term outcomes in patients with persistent EBV-DNA positivity after primary Epstein-Barr virus infection and clinical implications of rituximab therapy","volume":"156","author":"Liu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"116897","DOI":"10.1016\/j.diagmicrobio.2025.116897","article-title":"EBV-DNA load: a predictor of immune and hepatic dysfunction in pediatric infectious mononucleosis","volume":"113","author":"Liu","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e70491","DOI":"10.1002\/jmv.70491","article-title":"Unveiling the immune landscape: single-cell sequencing of infectious mononucleosis patients","volume":"97","author":"Liang","year":"2025","journal-title":"J Med Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1060053","DOI":"10.3389\/fped.2023.1060053","article-title":"Characteristics of immunological events in Epstein-Barr virus infection in children with infectious mononucleosis","volume":"11","author":"Zhang","year":"2023","journal-title":"Front Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e13059","DOI":"10.1002\/jgh3.13059","article-title":"Clinical utility of C-reactive protein-to-albumin ratio in the management of patients with inflammatory bowel disease","volume":"8","author":"Nguyen","year":"2024","journal-title":"JGH Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjmed.2019.10.031","article-title":"Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study","volume":"133","author":"Eckart","year":"2020","journal-title":"Am J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6304189","DOI":"10.1155\/2021\/6304189","article-title":"Early prediction of disease progression in patients with severe COVID-19 using C-reactive protein to albumin ratio","volume":"2021","author":"Li","year":"2021","journal-title":"Dis Markers"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.7150\/ijms.52405","article-title":"Optimized combination of circulating biomarkers as predictors of prognosis in AECOPD patients complicated with heart failure","volume":"18","author":"Yao","year":"2021","journal-title":"Int J Med Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3760\/cma.j.cn112140-20210618-00513","article-title":"Experts consensus on diagnosis and treatment of Epstein-Barr virus infection-related diseases in children","volume":"59","year":"2021","journal-title":"Chin J Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1003697","DOI":"10.3389\/fphar.2022.1003697","article-title":"Efficacy and safety of glycyrrhizic acid preparation treating comorbid liver injury in COVID-19: a systematic review","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B14","volume-title":"Defining, Establishing, and Verifying Reference Intervals of Quantitative Analytes in the Clinical Laboratory: WS\/T 402-2024","year":"2024"},{"key":"B15","unstructured":"Drug-Induced Liver Injury: Premarketing Clinical Evaluation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3760\/cma.j.cn112140-20240728-00523","article-title":"Guidelines for the management of community-acquired pneumonia in children (2024revision)","volume":"62","year":"2024","journal-title":"Chin J Pediatr"},{"key":"B17","volume-title":"Zhufutang Practice of Pediatrics","author":"Wang","year":"2022"},{"key":"B18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.virs.2022.07.007","article-title":"Epidemiological characteristics and disease burden of infectious mononucleosis in hospitalized children in China: a nationwide retrospective study","volume":"37","author":"Liu","year":"2022","journal-title":"Virol Sin"},{"key":"B19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-3-319-22822-8_9","article-title":"Infectious mononucleosis","volume":"390","author":"Dunmire","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.12010\/j.issn.1673-5846.2024.09.010","article-title":"High risk factors for liver function caused by pediatric infectious mononucleosis","volume":"19","author":"Chen","year":"2024","journal-title":"China J Pharm Econ"},{"key":"B21","unstructured":"Correlation and clinical significance of changes in serum soluble P-selectin, D-dimer and platelet levels with the severity of mycoplasma pneumoniae infection in children\n          \n          244\n          9\n          \n            \n              Li\n              M\n            \n            \n              Gao\n              J\n            \n          \n          Altern Ther Health Med\n          31\n          2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1186\/s12879-025-11440-1","article-title":"Elevated CD4+\/CD8+ ratio and D-dimer as diagnostic biomarkers for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis versus infectious mononucleosis in children: a retrospective case-control study","volume":"25","author":"Cheng","year":"2025","journal-title":"BMC Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaci.2024.11.029","article-title":"Features of hyperinflammation link the biology of Epstein-Barr virus infection and cytokine storm syndromes","volume":"155","author":"Liu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.5937\/jomb0-54625","article-title":"Elevated interleukin-10,\u221222,\u221224, and\u221226 in serum samples of children with infectious mononucleosis","volume":"44","author":"Li","year":"2025","journal-title":"J Med Biochem"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1830883\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:43:58Z","timestamp":1778823838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1830883\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":24,"alternative-id":["10.3389\/fmed.2026.1830883"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1830883","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1830883"}}